Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in HR+/HER2- Metastatic Breast Cancer (ARIANNA)
NCT04142060Phase 2Terminated
- Sponsor
- SOLTI
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in breast cancer, sponsored by SOLTI. Primary endpoint: Changes of the PAM50 11-gene proliferation signature at 2 weeks. Started Jun 2020; status: terminated.
02
Drugs
enzalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04142060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142060.